Media Report That SFDA's Zhang Jingli, Suspected Of Bribery, Might Have Received Payments From Johnson & Johnson
This article was originally published in PharmAsia News
Executive SummaryMedia reports recently have stated that the case of former SFDA Deputy Commissioner Zhang Jingli, now subject to a Central Commission for Discipline Inspection bribery investigation, might have involved Shanghai Johnson & Johnson Medical and a number of other medical device companies
You may also be interested in...
Perrigo has received US FDA approval for a generic version of Teva’s ProAir albuterol inhaler. The firm is immediately launching a “limited quantity” but is also ramping up production with partner Catalent to meet future demand.
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
Neuraxpharm has struck a deal to acquire Glenmark’s CNS portfolio in Poland. As part of the agreement, Glenmark’s Jacek Sawicki has been named as general manager of Neuraxpharm Polska and will lead a business that now incorporates Glenmark’s CNS commercial team.